Structural and Molecular Interaction Studies on Familial Hypercholesterolemia Causative PCSK9 Functional Domain Mutations Reveals Binding Affinity Alterations with LDLR

被引:0
|
作者
Zuhier Ahmed Awan
Rawabi Bahattab
Hussam Ibrahim Kutbi
Ahmad Omar Jamal Noor
Marzog S. Al-Nasser
Noor Ahmad Shaik
Babajan Banaganapalli
机构
[1] King Abdulaziz University,Department of Clinical Biochemistry, Faculty of Medicine
[2] King Abdulaziz University,Department of Genetic Medicine, Faculty of Medicine
[3] King Abdulaziz University,Princess Al
[4] King Abdulaiziz University,Jawhara Center of Excellence in Research of Hereditary Disorders
[5] King Abdulaziz University,Department of Pharmacy Practice, Faculty of Pharmacy
关键词
PCKS9; Familial hypercholesterolemia; Protein–protein interaction; Protein structural network; Molecular docking;
D O I
暂无
中图分类号
学科分类号
摘要
Familial hypercholesterolemia (FH) is a metabolic disease caused by the inherited pathogenic mutations in PCSK9 gene. This study has evaluated the potential of diverse computational methods in predicting the PCSK9 clinical variants and also studied the impacts of mutation on protein phenotype and function. Our findings show the superior prediction ability of FATHMM over CADD, M-CAP, SIFT and Polyphen methods, in screening PCSK9 missense mutations causative to FH. Computational 3D mapping of PCSK9 variants located in prodomain (K83T), catalytic domain (D204N) and c-terminal domains (K494E) revealed mutant residue induced disturbances in the tertiary structure of protein. These variants are also predicted to impair the free energy dynamics, hence stability of PCKS9 as per the consensual predictions made by protein structure-based prediction algorithms like SAAFEC and MAESTRO. Molecular docking assay by PIZMA algorithm showed the increased binding affinity between PCSK9 variants and LDLR molecules. Furthermore, the results from PDBsum method have also suggested changes in interfacing residues, interface area, salt bridge and ionic bond interactions confirming the findings from docking analysis. The PCSK9 functional domain mutations could increase its binding affinity with LDLR, eventually promoting LDLR degradation in lysosomes and elevate circulating cholesterol levels in body. This study supports the application of comprehensive computational assessment of FH causative PCSK9 mutations before undertaking labor intensive functional biology investigations.
引用
收藏
页码:719 / 733
页数:14
相关论文
共 17 条
  • [11] Identification and molecular characterization of new PCSK9 missense mutations associated with familial hypercholesterolemia
    Homer, Vivienne
    Marais, David
    Laurie, Andrew
    Charlton, Francesca
    Sullivan, David
    Barter, Philip
    Rye, Kerry-Anne
    George, Peter
    Lambert, Gilles
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E122 - E122
  • [12] LDLR and PCSK9 3´UTR variants and their putative effects on microRNA molecular interactions in familial hypercholesterolemia: a computational approach
    Renata Caroline Costa de Freitas
    Raul Hernandes Bortolin
    Jessica Bassani Borges
    Victor Fernandes de Oliveira
    Carolina Dagli-Hernandez
    Elisangela da Silva Rodrigues Marçal
    Gisele Medeiros Bastos
    Rodrigo Marques Gonçalves
    Andre Arpad Faludi
    Vivian Nogueira Silbiger
    André Ducati Luchessi
    Rosario Dominguez Crespo Hirata
    Mario Hiroyuki Hirata
    Molecular Biology Reports, 2023, 50 : 9165 - 9177
  • [13] LDLR and PCSK9 3′ UTR variants and their putative effects on microRNA molecular interactions in familial hypercholesterolemia: a computational approach
    de Freitas, Renata Caroline Costa
    Bortolin, Raul Hernandes
    Borges, Jessica Bassani
    de Oliveira, Victor Fernandes
    Dagli-Hernandez, Carolina
    Marcal, Elisangela da Silva Rodrigues
    Bastos, Gisele Medeiros
    Goncalves, Rodrigo Marques
    Faludi, Andre Arpad
    Silbiger, Vivian Nogueira
    Luchessi, Andre Ducati
    Hirata, Rosario Dominguez Crespo
    Hirata, Mario Hiroyuki
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (11) : 9165 - 9177
  • [14] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9) V4I VARIANT WITH LDLR MUTATIONS MODIFIES THE PHENOTYPE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Hori, M.
    Ohta, N.
    Takahashi, A.
    Ogura, M.
    Makino, H.
    Tamanaha, T.
    Miyamoto, Y.
    Harada-Shiba, M.
    ATHEROSCLEROSIS, 2016, 252 : E35 - E36
  • [15] Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study
    Iannuzzo, Gabriella
    Buonaiuto, Alessio
    Calcaterra, Ilenia
    Gentile, Marco
    Forte, Francesco
    Tripaldella, Maria
    Di Taranto, Maria D.
    Giacobbe, Carola
    Fortunato, Giuliana
    Rubba, Paolo O.
    Di Minno, Matteo N. Dario
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (03) : 684 - 691
  • [16] No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes
    Damgaard, D
    Jensen, JM
    Larsen, ML
    Soerensen, VR
    Jensen, HK
    Gregersen, N
    Jensen, LG
    Faergeman, O
    ATHEROSCLEROSIS, 2004, 177 (02) : 415 - 422
  • [17] Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia
    Bai, Zhengli
    Xu, Menglong
    Mei, Ying
    Hu, Tuo
    Zhang, Panpan
    Chen, Manman
    Lv, Wenxiu
    Lu, Chenchen
    Tan, Shuhua
    BIOMEDICINES, 2021, 9 (12)